FDA approves FoundationOne((R))CDx as an adjunct diagnostic Test for Vitrakvi((R)) (larotrectinib) to aid in the Identification of NTRK-Fusion-positive Patients-MedSci.cn

FDA approves FoundationOne((R))CDx as an adjunct diagnostic Test for Vitrakvi((R)) (larotrectinib) to aid in the Identification of NTRK-Fusion-positive Patients

[Anonymous]

ONCOLOGY RESEARCH AND TREATMENT, 2020; 43 (12): 716

科室
- - 订阅+
  - 更多科室
工具
服务